Cipla reported record Q1 FY27 revenue of ₹7,119 crore, up 2% year-on-year. However, EBITDA margins declined to 16.7% due to upfront product launch costs and inflation. Management maintained FY27 EBITDA margin guidance, expecting sequential improvement.
Detailed Coverage
Cipla Reports Record Q1 FY27 Revenue of ₹7,119 Crore Amidst Margin Pressures
Cipla announced its Q1 FY27 financial results, achieving a record quarterly revenue of ₹7,119 crore. This represents a 2% year-on-year growth, or 4% adjusted for certain factors. ## What just happened Cipla's revenue for the first quarter of FY27 reached ₹7,119 crore. The company's EBITDA margin stood at 16.7%, with a Profit After Tax (PAT) of ₹789 crore. Total expenses were ₹3,260 crore. Research and Development (R&D) investment amounted to ₹486 crore, representing 6.8% of revenue. The effective tax rate was 27%. ## Why this matters Despite the record revenue, the lower EBITDA margin signals short-term cost pressures. However, the company's reaffirmation of its FY27 EBITDA margin guidance of 18.5% to 20% suggests management's confidence in future profitability improvements. Investors will be keen to see the impact of upcoming product launches, particularly in the North American market. ## The backstory The One India business showed robust growth of 12% year-on-year, driven by its chronic portfolio. In North America, revenue was USD 162 million. Management is targeting a USD 1 billion exit run rate by FY27 end for this market, with plans for respiratory and peptide asset launches. Commercial shipments for generic Ventolin have commenced. ## What changes now Cipla is in a 'transit phase' with significant upfront costs for new product launches and the impact of inflation. These factors led to the current margin dip. Management anticipates sequential improvement in margins in the upcoming quarters as these costs are absorbed and new products gain traction. ## Risks to watch While the US revenue target remains on track, potential delays in product approvals or lower-than-expected market adoption for the four upcoming launches could pose a risk. Performance in South Africa was affected by tender losses, although the private market showed resilience with 6.5% growth. ## Peer comparison (No direct peer comparison data available in the filing). ## Context metrics (time-bound) * **Q1 FY27 Revenue:** ₹7,119 crore (2% YoY growth, 4% adjusted) * **Q1 FY27 EBITDA Margin:** 16.7% * **Q1 FY27 PAT:** ₹789 crore * **Q1 FY27 R&D Investment:** ₹486 crore (6.8% of revenue) * **North America Revenue (Q1 FY27):** USD 162 million * **FY27 EBITDA Margin Guidance:** 18.5% - 20% ## What to track next Investors should monitor upcoming US product approvals and their commercial success, the progress towards the USD 1 billion North American revenue run rate, and the sequential improvement in EBITDA margins throughout the fiscal year.
